Evolocumab

PCSK9 Inhibitor — CARDIOVASCULAR SYSTEM

Key facts

Evolocumab is a drug in the PCSK9 Inhibitor class catalogued in DrugCentral. It was first approved by the EMA in 2015. Its mechanism of action is classified as PCSK9 Inhibitors. DrugCentral lists 1 molecular target, including PCSK9. Recorded indications include Cardiovascular disease, Complex dyslipidemia, Familial hypercholesterolemia - heterozygous and Familial hypercholesterolemia - homozygous.

• Drug class: PCSK9 Inhibitor.
• Mechanism of action: PCSK9 Inhibitors.
• Molecular targets: PCSK9 (1 listed in DrugCentral).
• Indications: Cardiovascular disease, Complex dyslipidemia, Familial hypercholesterolemia - heterozygous, Familial hypercholesterolemia - homozygous and Hypercholesterolemia.
• ATC code: C10AX13 (Other lipid modifying agents).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (5)

• Cardiovascular disease
• Complex dyslipidemia
• Familial hypercholesterolemia - heterozygous
• Familial hypercholesterolemia - homozygous
• Hypercholesterolemia

Mechanism & targets

• Mechanism of action (MoA): PCSK9 Inhibitors
• Established pharmacologic class: PCSK9 Inhibitor

Molecular targets (1)

Target	Gene	Action	Activity
Proprotein convertase subtilisin/kexin type 9	PCSK9	inhibitor	Kd 9.72

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2016-01-22	PMDA	—	Astellas Pharma
2015-08-28	FDA	—	REPATHA
2015-05-21	EMA	—	—

ATC classification

ATC code	Therapeutic hierarchy
C10AX13	CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, PLAIN › Other lipid modifying agents

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label
• FDA label
• HCSC label

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Device difficult to use	30067.6
Wrong technique in product usage process	29157.7
Accidental exposure to product	20487.0
Drug dose omission by device	16653.3
Injection site pain	11175.1
Product storage error	7074.9
Injection site bruising	6617.8
Product dose omission issue	5243.7
Injection site haemorrhage	5023.6
Myalgia	4994.6
Device use error	4201.5
Incorrect dose administered by device	4136.3

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 1256937-27-5
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Evolocumab used for?

DrugCentral lists the following indications for Evolocumab: Cardiovascular disease, Complex dyslipidemia, Familial hypercholesterolemia - heterozygous, Familial hypercholesterolemia - homozygous and Hypercholesterolemia.

How does Evolocumab work?

Evolocumab is classified as PCSK9 Inhibitors; its molecular targets in DrugCentral include PCSK9 (inhibitor).

When was Evolocumab first approved?

Evolocumab was first approved by the EMA in 2015.

What drug class does Evolocumab belong to?

Evolocumab is in the PCSK9 Inhibitor class.

Sources

• DrugCentral drug card 5000 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2364655 — compound record and bioactivity
• DrugBank DB09303 — drug record
• FDA UNII LKC0U3A8NJ — substance identity
• DailyMed: FDA labels for Evolocumab — current prescribing information (label search)
• UniProt Q8NBP7 (PCSK9) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.